Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim–sulfamethoxazole, a prophylactic agent for P. jiroveci pneumonia, in patients with connective tissue diseases
Tóm tắt
Trimethoprim–sulphamethoxazole (TMP–STX), an agent used for prophylaxis against pneumocystis pneumonia (PCP) in immunocompromised hosts, causes serious adverse effects (AEs) in some patients. The objective of this study was to identify the risk factors for AEs caused by TMP–STX in connective tissue disease (CTD) patients and to describe the clinical features of the AEs. The medical records of 539 patients (CTDs 312, pulmonary diseases 227) receiving TMP–STX for prophylaxis against PCP were reviewed retrospectively. Patients with human immunodeficiency virus were excluded. Univariate and multivariate analyses were conducted to identify the risk factors. Adverse events caused by TMP–STX occurred in 22 of 312 (7.05 %) CTD patients, while only six of 227 (2.64 %) pulmonary disease patients developed AEs. The incidence of AEs was significantly higher in systemic lupus erythematosus (SLE) (11.0 %) and mixed connective tissue disease (MCTD) (33.3 %) patients than in other CTD patients. AEs occurred in 25 % of patients with anti-RNP antibody. Univariate analysis revealed that SLE, MCTD, and anti-RNP antibody were risk factors for AEs in CTD patients. Further multivariate analyses demonstrated that only anti-RNP antibody positivity was a risk factor for AEs. Systemic inflammation, including fever, was a characteristic manifestation of the AEs in CTD patients, particularly those with anti-RNP antibody. Positivity for anti-RNP antibody is a risk factor for AEs caused by TMP–STX in CTD patients. Systemic inflammation, including fever, might be a characteristic feature of the AEs in CTD patients, particularly those with anti-RNP antibody.
Tài liệu tham khảo
Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487–98.
Catherinot E, Lanternier F, Bougnoux ME, Lecuit M, Couderc LJ, Lortholary O. Pneumocystis jirovecii pneumonia. Infect Dis Clin North Am. 2010;24:107–38.
Godeau B, Coutant-Perronne V, Le Thi Huong D, Guillevin L, Magadur G, De Bandt M, Dellion S, Rossert J, Rostoker G, Piette JC, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol. 1994;21:246–51.
Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999;42:780–9.
Falagas ME, Manta KG, Betsi GI, Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol. 2007;26:663–70.
Walzer PD, Smulian AG. Pneumocystis species. In: Mandel GL, Bennett JE, Dolin R (eds) Mandel, Douglas and Bennett’s principles and practice of infectious diseases, vol. 2. 6th edn. Philadelphia: Churchill Livingstone; 2004. p. 3080–94.
Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest. 2000;118:704–11.
Harigai M, Koike R, Pneumocystis Pneumonia under Anti-Tumor Necrosis Factor Therapy (PAT) Study Group. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007;357:1874–6.
Sowden E, Carmichael AJ. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect Dis. 2004;4:42.
Suryaprasad A, Stone JH. When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insight from three cases complicating autoimmune diseases. Arthritis Rheum. 2008;59:1034–9.
Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2007;18:CD005590.
Takabayashi K, Kurasawa K, Yamazaki S, Sugiyama T, Matsumura R,Yoshida H, Koike T, et al. Pulmonary opportunistic infections in patients with autoimmune diseases (in Japanese). Nihon Naika Gakkai Zasshi. 1989;78:1293–8.
Reilly TP, Ju C. Mechanistic perspectives on sulfonamide-induced cutaneous drug reactions. Curr Opin Allergy Clin Immunol. 2002;2:307–1.
Jaffe HS, Abrams DI, Ammann AJ, Lewis BJ, Golden JA. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet. 1983;22:1109–11.
Ryan TM. Significance tests for multiple comparison of proportions, variances, and other statistics. Psychol Bull. 1960;5:318–28.
Jick H. Adverse reactions to trimethoprim–sulfamethoxazole in hospitalized patients. Rev Infect Dis. 1982;4:426–8.
Shionogi (Osaka, Japan). Baktar. Drug interview form (in Japanese). 2009. Available at: http://www.info.pmda.go.jp/go/interview/1/340018_6290100D1088_1_008_1F.
Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100:663–71.
Davis CM, Shearer WT. Diagnosis and management of HIV drug hypersensitivity. J Allergy Clin Immunol. 2008;121:826–32.
Lin D, Li WK, Rieder MJ. Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole. Cochrane Database Syst Rev. 2007;2:CD005646.
Antonen JA, Markula KP, Pertovaara MI, Pasternack AI. Adverse drug reactions in Sjögren’s syndrome. Frequent allergic reactions and a specific trimethoprim-associated systemic reaction. Scand J Rheumatol. 1999;28:157–9.
Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim–sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996;335:16–20.
Pope J, Jerome D, Fenlon D, Krizova A, Ouimet J. Frequency of adverse drug reactions in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:480–4.
Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK, Nielsen TL, van der Graaf Y, Frissen JP, van der Ende IM, Kolsters AF, Borleffs JC. A controlled trial of aerosolized pentamidine or trimethoprim–sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med. 1992;327:1836–41.
Hardy WD, Feinberg J, Finkelstein DM, Power ME, He W, Kaczka C, Frame PT, Holmes M, Waskin H, Fass RJ, et al. A controlled trial of trimethoprim–sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med. 1992;327:1842–8.
Okada J, Kadoya A, Rana M, Ishikawa A, Iikuni Y, Kondo H. Efficacy of sulfamethoxazole–trimethoprim administration in the prevention of Pneumocystis carinii pneumonia in patients with connective tissue disease. Kansenshogaku Zasshi. 1999;73:1123–9.
Soejima M, Sugiura T, Kawaguchi Y, Kawamoto M, Katsumata Y, Takagi K, Nakajima A, Mitamura T, Mimori A, Hara M, Kamatani N. Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus. Arthritis Res Ther. 2007;9:R23.
Reilly TP, Ju C. Mechanistic perspectives on sulfonamide-induced cutaneous drug reactions. Curr Opin Allergy Clin Immunol. 2002;2:307–15.
Naisbitt DJ, Farrell J, Gordon SF, Maggs JL, Burkhart C, Pichler WJ, Pirmohamed M, Park BK. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol Pharmacol. 2002;62:628–37.
Eloranta ML, Lövgren T, Finke D, Mathsson L, Rönnelid J, Kastner B, Alm GV, Rönnblom L. Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum. 2009;60:2418–27.
Okada J, Hamana T, Kondo H. Anti-U1RNP antibody and aseptic meningitis in connective tissue diseases. Scand J Rheumatol. 2003;32:247–52.
Fujita Y, Fujii T, Nakashima R, Tanaka M, Mimori T. Aseptic meningitis in mixed connective tissue disease: cytokine and anti-U1RNP antibodies in cerebrospinal fluids from two different cases. Mod Rheumatol. 2008;18:184–8.
Joffe AM, Farley JD, Linden D, Goldsand G. Trimethoprim–sulfamethoxazole-associated aseptic meningitis: case reports and review of the literature. Am J Med. 1989;87:332–8.
Gilroy N, Gottlieb T, Spring P, Peiris O. Trimethoprim-induced aseptic meningitis and uveitis. Lancet. 1997;350:112.
Kimura M, Tanaka S, Ishikawa A, Endo H, Hirohata S, Kondo H. Comparison of trimethoprim–sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease. Rheumatol Int. 2008;28:673–6.